Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFZ533 with or without tacrolimus in de novo renal transplant recipients
2015-000925-36Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iscalimab in kidney allograft rejection (2 arms), sponsored by Novartis. Primary endpoint: Safety, tolerability and pharmacokinetics of CFZ533 in combination with MMF, CS, and tacrolimus (Part 1). Started Nov 2015; status: completed.
02
Drugs
iscalimab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2015-000925-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000925-36.